Abstract
Most luminal breast carcinomas (BrCas) bearing PIK3CA mutations initially respond to phosphoinositide-3-kinase (PI3K)-alpha inhibitors, but many event......
小提示:本篇文献需要登录阅读全文,点击跳转登录